Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2013-08-15 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2013年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2013 半年度报告摘要' which translates to '2013 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and shareholder information. It also includes management discussion and analysis of the company's performance during the period. The document is about 3213 characters long, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The content matches the characteristics of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year and includes actual financial statements and management commentary. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2013
2013-08-15 Chinese
第五届董事会第五次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding several decisions made at a board meeting, including approval of the 2013 semi-annual report and its summary, proposals related to capital increase, amendments to the company bylaws, and the scheduling of a shareholders meeting. The document references the 2013 semi-annual report but does not contain the report itself; instead, it states that the full report and summary are available on the company's disclosure website and in a newspaper. The document is relatively short (2204 characters) and serves as an official announcement of board resolutions and related corporate governance matters. It is not the semi-annual report itself, nor a full interim report with financial statements. The document also includes amendments to the company bylaws, which is related to governance but primarily it is a board meeting resolution announcement. Given these factors, the document best fits the category of Regulatory Filings (RNS), as it is a general regulatory announcement of board meeting resolutions and related corporate actions without containing the full financial report or detailed financial data.
2013-08-15 Chinese
独立董事关于公司第五届董事会第五次临时会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Beijing SL Pharmaceutical Co., Ltd. regarding specific matters discussed at the company's fifth board meeting. It references regulatory guidelines from the China Securities Regulatory Commission and discusses compliance with laws and company rules related to external guarantees, related party transactions, and entrusted loans. The document is relatively short (1500 characters) and focuses on governance and compliance opinions rather than presenting financial statements or detailed financial results. It does not contain financial data or results but rather an independent directors' opinion on specific governance and compliance issues. This fits best under the category of Board/Management Information (MANG), which includes announcements related to board matters and management opinions. It is not an Annual Report, Audit Report, or Regulatory Filing as it is a formal opinion document from the board's independent directors on specific governance matters.
2013-08-15 Chinese
2013年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2013 半年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2013 Semi-Annual Report Full Text." It contains detailed financial data, including revenue, net profit, cash flow, investment activities, and management discussion. The report covers the period from January 1, 2013, to June 30, 2013, which is a half-year period. The content includes financial statements, management analysis, business overview, investment details, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2013
2013-08-15 Chinese
关于召开2013年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2013 first extraordinary general meeting (临时股东大会) of Beijing SL Pharmaceutical Co., Ltd. It includes details about the meeting date, agenda items (capital increase, amendment of articles of association, and loan authorization), registration procedures, and proxy voting. The document is a formal announcement to shareholders about the meeting and does not contain financial statements, management discussion, or voting results. It is not a report or transcript but a meeting notice. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2013-08-15 Chinese
关于全资子公司对外委托贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a loan transaction by a wholly-owned subsidiary of the company. It details the terms of the entrusted loan, the parties involved, the decision-making process, risk control measures, and independent directors' opinions. It also mentions the need for shareholder approval due to the related-party nature of the transaction. The document is relatively short (4165 characters) and focuses on a specific financing transaction rather than presenting comprehensive financial statements or results. There is no indication that this is a full financial report, audit report, or earnings release. The content fits the description of a Capital/Financing Update, as it provides updates on financing activities and capital structure changes related to entrusted loans. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2013-08-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.